Pricing Log in Create free account
Friday 6 November 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS
+63.2%
Free cash flow
−112.8%

Quarter to June 2026, against a year earlier

16.13 1.94 +13.67%
Market cap
$11.3B
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
0.88
Beneish M
−5.00
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Summit Therapeutics PLC 10-Q filed Jul 23, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 4:08 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Apr 30, 2026: no changes; 1 with only figures updated